Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.59 |
| ▸ | PPARA | Q07869 | 4/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23308028 | 0.86 | PPARA (0.47) | CYP4F2CYP4A11PPARAPPARGHRH3 | |
| SCHEMBL3175607 | 0.83 | CYP4F2 (0.65) | CYP4F2CYP4A11PPARAPPARGALOX5 | |
| SCHEMBL29200252 | 0.82 | CYP4F2 (0.55) | CYP4F2CYP4A11PPARAPPARG | |
| SCHEMBL30771521 | 0.82 | CYP4F2 (0.55) | CYP4F2CYP4A11PPARAPPARG | |
| SCHEMBL13791088 | 0.81 | NLRP3 (0.47) | PPARAPPARGHRH3NLRP3 | |
| SCHEMBL3255549 | 0.81 | KMT2A (0.51) | PPARAPPARGNLRP3 | |
| SCHEMBL21069039 | 0.80 | PPARA (0.45) | CYP4F2CYP4A11PPARAPPARGHRH3 | |
| SCHEMBL3254928 | 0.79 | MAOB (0.51) | PPARAPPARGNLRP3 | |
| SCHEMBL7035447 | 0.79 | HCAR2 (0.49) | PPARAPPARG | |
| SCHEMBL3254957 | 0.78 | PPARA (0.52) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491623-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | CYP4F2 107/4885CYP4A11 355/4885PPARA 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.